GITMO AML/MDS-Relapse Registry Study

Plain-language summary

This registry study examined the course of patients with acute myeloid leukemia and myelodysplastic syndrome who relapsed after stem cell transplantation. It included patients who underwent allogeneic stem cell transplant between 2015 and 2021, relapsed, and received salvage therapy. It is a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Gruppo Italiano Trapianto di Midollo Osseo

Start date

12/15/2022

Estimated completion

5/9/2024

Countries

Italy

Related genes

Locations

• Bologna, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All patients with AML and MDS who underwent allo-SCT from 2015 to 2021, who relapsed and received salvage therapy for the relapse.

Exclusion Criteria:

* Patients with a diagnosis other than AML and MDS transplanted in the same period.